TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage biopharmaceutical company developing RNA-based therapeutics and immuno-oncology treatments for high-risk and advanced cancers, announced that its board of directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its oncology portfolio, including lead product candidate TTX-MC138. The review will consider potential licensing or sales of individual assets, development and commercialization partnerships, portfolio transactions, business combinations and other strategic alternatives. TransCode has engaged Tungsten Advisors as its exclusive strategic financial adviser for the process.
TTX-MC138, an investigational RNA-based therapeutic targeting microRNA-10b, has advanced into Phase 2a clinical development following a Phase 1a study that provided initial safety data and reports of stable disease. The ongoing trial is evaluating the treatment in patients with circulating tumor DNA-positive colorectal cancer following curative-intent therapy, in collaboration with Quantum Leap Healthcare Collaborative. TransCode also recently announced a collaboration with Natera Inc. to use its Signatera test to identify eligible patients and support trial enrollment.
Chairman and CEO Philippe P. Calais said the strategic review is intended to identify opportunities to advance the company’s oncology programs while seeking to maximize stockholder value. TransCode cautioned that the process may not result in a transaction or other strategic outcome. The announcement signals a potential shift in strategy for the company, which has focused on developing a portfolio of first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
For investors, the strategic review could lead to significant changes in the company’s structure or ownership, but the cautionary note underscores the uncertainty of such processes. The news comes as TransCode continues to advance its clinical programs, with TTX-MC138 being tested in a Phase 2a trial. The company’s focus on microRNA-10b, a unique and well-documented biomarker of metastasis, positions it in the competitive field of RNA therapeutics. The full press release can be viewed at https://ibn.fm/AGxas. For the latest news and updates relating to RNAZ, visit the company’s newsroom at https://ibn.fm/RNAZ.
The announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. The platform offers editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to millions of followers. These services are part of a suite of corporate communications solutions designed to help companies reach a wide audience.
